Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

PharmaZen forecasts 44% jump in 2018 sales

PharmaZen forecasts 44% jump in 2018 sales as new plant allows toll processing

By Jonathan Underhill

May 16 (BusinessDesk) - PharmaZen, a Christchurch-based manufacturer of plant and animal-based health supplements, is forecasting a 44 percent increase in sales this year and a jump in earnings as the company brings a new plant online.

Turnover at its Waitaki Biosciences operating division is forecast to rise to $10.5 million this year from $7.3 million in 2017, according to a presentation to shareholders at their annual meeting this month. Earnings before interest, tax, depreciation and amortisation is seen rising to $2.5 million from $443,000 while pre-tax profit is $1.5 million from a $352,000 loss in 2017 when major delays installing a new freeze drier disrupted production.

A five-year, $12.5 million capital investment will result in PharmaZen having the largest solvent extraction plant in New Zealand and the biggest freeze drier plant in Australasia with the capacity to dry 3,000 metric tonnes of frozen product a year, it says.

According to the AGM presentation, the company is in the final stages of gaining a licence from Medsafe to produce MCHCal and StimuCal - products aimed at promoting bone health. Its other products include ActiPhen, a freeze-dried kiwifruit powder for digestive health, CassiPure, a blackcurrant extract and PernaTec oil and powder extracted from greenshell mussels.

"What we're experiencing now, in some cases, is quite unprecedented demand," said Steve Caultron, general manager at Waitaki. "We've got some fairly significant opportunities ahead of us in completely new markets where their volume expectations take us to a new level."

In PharmaZen's 2017 annual report, posted on the Unlisted Securities Exchange (USX) where its shares trade, the company said it is "now moving into its next phase including the development of new products. We anticipate an acceleration in investment in intellectual property with significant clinical trial work already scheduled for 2018 and 2019."

The company was likely to review its capitalisation policy "in order that the balance sheet better reflects the significant value in intellectual property that PharmaZen now possesses." It raised $2.4 million in equity capital in the final quarter of 2017 and said it was in talks with strategic partners for additional placements. Total borrowings stood at $8.1 million at year-end, up from $5.5 million a year earlier.

The company now had "an exceptional opportunity" to "increase its presence in the global nutraceutical market," it said in its annual report, which was released on March 26.

PharmaZen shares last traded on Unlisted at 7 cents, giving the company a market value of $13.7 million.

(BusinessDesk)

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

You'd Hope: Employers Told To Pay Minimum Wage

Advertisers offering jobs to backpackers are being told they must pay the minimum wage or risk prosecution. Last week, RNZ revealed a job website - Backpackerboard - was advertising roles below the $16.50 per hour minimum wage. More>>

ALSO:

Still Gaining: More Migrants Head Back Overseas

Annual net migration is down 4,800 from a high point a year ago, largely because more non-New Zealand citizens are leaving the country, Stats NZ said today. More>>

Christchurch: Red Zone Used To Boost Endangered Bee Population

“May 20 has been declared World Bee Day by the United Nations, and I am pleased to announce today that we have been able to use the red zone to protect and grow our native bee stocks,” says Minister Megan Woods. More>>

Trips, Support, Conferences For Agents: Insurers Spend $34 Million On Soft Commissions

“We are concerned that insurers are designing and offering incentives that potentially set advisers up to fail in complying with their obligations.” More>>

ALSO:

Privacy Commissioner: Facial Recognition Tech Not Reliable

The Privacy Commissioner says businesses should take great care when using facial recognition technology because there is a high risk of misidentification. More>>

Compliance Costs: Cheesemakers "Have A Reason To Smile"

Delighted to be a guest at The Great Eketahuna Cheese Festival today, Mr O’Connor launched the Food Safety Template for Cheesemakers – a tool to help cheesemakers producing cheese for New Zealand and Australia to meet food safety requirements. More>>